Cardurion Pharmaceuticals

PDE9/cardiac-signaling therapeutics for heart failure

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
PDE9Small molecule
Heart Failure

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

11 October 2026Topline resultTovinontrineCycle-1 REF Phase 2: tovinontrine reduced NT-proBNP at 2.5 mg and 25 mg BID in HFrEF; no benefit at 50 mg BID
Cardurion Pharmaceuticals · Source ↗
11 October 2026Topline resultTovinontrineCycle-2 PEF Phase 2: no significant change in NT-proBNP with tovinontrine 50 mg BID in HFpEF
Cardurion Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.